Article Information
History
- December 24, 2020.
Article Versions
- Version 1 (December 3, 2020 - 02:49).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Jack Ferguson1,+,
- Steven Dunn2,+,
- Angus Best3,+,
- Jeremy Mirza3,
- Benita Percival3,
- Megan Mayhew3,
- Oliver Megram3,
- Fiona Ashford3,
- Thomas White3,
- Emma Moles-Garcia3,
- Liam Crawford3,
- Tim Plant3,
- Andrew Bosworth4,
- Michael Kidd5,
- Alex Richter1,
- Jonathan Deeks6,7 and
- Alan McNally2,*
- 1Institute of Cancer and Genomic Science, College of Medical and Dental Science, University of Birmingham, Birmingham, UK
- 2Institute of Microbiology and Infection, College of Medical and Dental Science, University of Birmingham, Birmingham, UK
- 3Clinical Immunology Service, Institute of Immunology and Immunotherapy, College of Medical and Dental Science, University of Birmingham, Birmingham, UK
- 4University Hospital Birmingham NHS Foundation Trust, Birmingham, UK
- 5Public Health England, Birmingham, UK
- 6Institute of Applied Health Research, College of Medical and Dental Science, University of Birmingham, Birmingham, UK
- 7NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, UK
- ↵*Corresponding author: Prof Alan McNally, Institute of Microbiology and Infection, College of Medical and Dental Science, University of Birmingham, Edgbaston, Birmingham, B15 2TT. Tel: 0121 414 4368. Email: a.mcnally.1{at}bham.ac.uk
↵+ Authors contributed equally to the study
Posted December 24, 2020.
Validation testing to determine the effectiveness of lateral flow testing for asymptomatic SARS-CoV-2 detection in low prevalence settings
